Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2023 Earnings Call Transcript

Antony Mattessich: I believe we will, yes. I mean, it’s an optimized formulation, better marrying the drug elution with the life of the insert. So, I don’t see why we would want to go with that formulation, but it’s just a better iteration of what we’ve done before for all indications.

Yi Chen : And do you expect the same safety profile during the first nine or ten months with more drugs to be delivered by this new formulation?

Antony Mattessich: Well, we’re comfortable that the amount that we’re delivering is well within the safety window. It is, as you probably heard me mention earlier, the elution rate that we have on this optimized formulation is about the same as we had on the three times 200 that we had in Australia. So, we certainly don’t expect any difference in safety. Having maybe a little less drug around at the end of the life of the insert actually might, not that we had safety issues with what we had before, but it certainly would give us greater confidence that there would be less drug moving around the vitreous at the end of the life of the insert.

Yi Chen : Okay. Thank you.

Antony Mattessich: Thank you.

Operator: I’m showing no further questions at this time. I would now like to turn the call back to Antony Mattessich for closing remarks.

Antony Mattessich: Well, thanks everybody for joining us today. I mean, if it’s not come through, we are unbelievably excited to have the SPA behind us now, that we have a clear roadmap. We’ve done a lot of planning, a lot of discussing with the FDA, a lot of educating of the market that we still need to do. But we really are in a situation now where we’re gone from really intense planning to really putting our head down and getting behind the execution of this trial. We have our sites that are excited to be able to join it. We actually are very lucky that we’re launching this trial in a period where there’s a lot of infrastructure, particularly in the U.S., that’s capable of doing wet AMD trials that are currently not being utilized at a very high rate. So we’re very eager to get started. We’re very eager to get this product to patients and just can’t wait to get going. So thank you so much for attending today.

Operator: Yes, thank you for your participation in today’s conference. It does conclude the program and you may now disconnect.